Drug · CHEMBL54

HALOPERIDOL

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. HALOPERIDOL. Drugs and targets, record CHEMBL54. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL54

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: HALOPERIDOL; ChEMBL
ChEMBL ID: CHEMBL54; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Dolpin, Dozic, Fortunan, Haldol, Haldol solutab, Haloperidol component of vesalium, Kentace, Keselen, Serenace; ChEMBL
Other names: Haloperidol decanoate impurity, haloperidol-, MCN-JR-1625, NSC-170973, NSC-615296, R-1625; ChEMBL
Other form: HALOPERIDOL LACTATE, CHEMBL4297147; Drugs and targets
DrugBank: DB00502; DrugBank
InChIKey: LNEPOXFFQSENCJ-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 6 of its 26 diseases, from ATC, DailyMed and TTD; Open Targets

Targets4

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
DRD2	D2-like dopamine receptor	D2-like dopamine receptor inverse agonist	INVERSE AGONIST	https://conductscience.org/library/genes/1813
DRD3	D2-like dopamine receptor	D2-like dopamine receptor inverse agonist	INVERSE AGONIST	https://conductscience.org/library/genes/1814
DRD4	D2-like dopamine receptor	D2-like dopamine receptor inverse agonist	INVERSE AGONIST	https://conductscience.org/library/genes/1815
HTR2A	5-hydroxytryptamine receptor 2A	Serotonin 2a (5-HT2a) receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/3356

Source ChEMBL

Diseases26

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
schizophrenia	Approval	DailyMed and TTD	40	33	https://conductscience.org/library/drugs?q=MONDO_0005090
delirium	Phase 3	ClinicalTrials.gov	22	22	https://conductscience.org/library/drugs?q=MONDO_0045057
Agitation	Phase 3	ClinicalTrials.gov	13	13	https://conductscience.org/library/drugs?q=HP_0000713
bipolar disorder	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0004985
schizoaffective disorder	Phase 2	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0005487
psychotic disorder	Approval	ATC and DailyMed	6	4	https://conductscience.org/library/drugs?q=MONDO_0005485
aggressive behavior	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=EFO_0003015
bipolar I disorder	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_0009963
major depressive disorder	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0002009
Tourette syndrome	Approval	DailyMed	3	1	https://conductscience.org/library/drugs?q=MONDO_0007661

1 to 10 of 26Source Open Targets

See all 26 diseases

Trials146

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT02625181	Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis		27,034	2019-03-07	haloperidol	Its name	ClinicalTrials.gov
NCT01211522	The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study	Phase 3	566	2019-08-20	haloperidol	Its name	ClinicalTrials.gov
NCT00842608	Pharmacological Management of Delirium		551	2017-03-24	haloperidol	Its name	ClinicalTrials.gov
NCT01157351	15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated	Phase 4	450	2014-12-04	haloperidol	Its name	ClinicalTrials.gov
NCT00723606	A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation	Phase 3	376	2010-08-25	haloperidol	Its name	ClinicalTrials.gov
NCT00044044	A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia	Phase 2	356	2011-04-12	haloperidol	Its name	ClinicalTrials.gov
NCT02431702	A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform	Phase 3	337	2021-01-19	haloperidol	Its name	ClinicalTrials.gov
NCT00129220	Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder	Phase 3	224	2010-02-15	haloperidol	Its name	ClinicalTrials.gov
NCT00156065	Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)	Phase 3	187	2010-04-07	haloperidol	Its name	ClinicalTrials.gov
NCT01639599	Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients		150	2020-08-24	haloperidol	Its name	ClinicalTrials.gov

1 to 10 of 146

See all 146 trials

Comparisons in its trials28

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Paliperidone Palmitate vs Oral Antipsychotics: serious adverse events	42 of 226	53 of 218	444	NCT01157351	Trial comparisons
Ziprasidone vs Haloperidol: serious adverse events	0 of 189	0 of 187	376	NCT00723606	Trial comparisons
Haloperidol vs Placebo: Efficacy of Low-dose Haloperidol in Reducing Delirium Incidence	15 of 68	19 of 67	135	NCT02213900	Trial comparisons
Haloperidol vs Placebo: serious adverse events	3 of 68	2 of 67	135	NCT02213900	Trial comparisons
Haloperidol + Promethazine + Chlorpromazine vs Haloperidol + Promethazine: Time Noted Where Important Adverse Effects Occurred Post Intervention	0 of 52	0 of 48	100	NCT03639558	Trial comparisons
Haloperidol + Promethazine + Chlorpromazine vs Haloperidol + Promethazine: deaths from any cause	0 of 52	0 of 48	100	NCT03639558	Trial comparisons
Haloperidol + Promethazine + Chlorpromazine vs Haloperidol + Promethazine: serious adverse events	0 of 52	0 of 48	100	NCT03639558	Trial comparisons
Intervention Group (Lorazepam & Haloperidol) vs Control Group (Placebo & Haloperidol): deaths from any cause	10 of 47	10 of 43	90	NCT01949662	Trial comparisons
Ziprasidone vs Sertraline/Haloperidol: serious adverse events	1 of 35	0 of 37	72	NCT00340379	Trial comparisons
Quetiapine vs Cocktail: serious adverse events	0 of 40	0 of 32	72	NCT00457366	Trial comparisons

1 to 10 of 28

See all 28 comparisons in its trials

Papers from its trials163

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37249604	RESULT	1	PubMed
36448276	RESULT	1	PubMed
35971024	RESULT	1	PubMed
35636044	RESULT	1	PubMed
35065334	RESULT	1	PubMed
34820831	RESULT	1	PubMed
34546899	RESULT	1	PubMed
34238838	RESULT	1	PubMed
33805916	RESULT	1	PubMed
33728561	RESULT	1	PubMed

1 to 10 of 163

See all 163 papers from its trials

Tests in its trials11

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Symbol Coding	2	0	ConductCognition
Category Fluency	1	0	ConductCognition
Dictator Game	1	1	ConductCognition
Digit Span Test	1	0	ConductCognition
Effort Discounting Task	1	0	ConductCognition
Picture Naming Test	1	0	ConductCognition
Simple Reaction Time	1	0	ConductCognition
Trail Making Test A	1	0	ConductCognition
Trail Making Test B	1	0	ConductCognition
Verbal Fluency	1	0	ConductCognition

1 to 10 of 11

See all 11 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL54

GET https://conductscience.org/api/drugs/v1/CHEMBL54/diseases?page=2

API reference For AI assistants